Hansa Biopharma AB
HNSA.STDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Imlifidase
Kidney Transplantation in Highly Sensitized Patients
Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
Long Term Efficacy and Safety
IdeS
End Stage Kidney Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Imlifidase | Phase 3 | Kidney Transplantation in Highly Sensitized Patients | - | - |
Imlifidase administered in the 20-HMedIdeS-19 (PAES) study | Phase 3 | Long Term Efficacy and Safety | - | - |
IdeS | Phase 2 | End Stage Kidney Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hansa Biopharma AB's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Hansa Biopharma AB's (HNSA.ST) pipeline across Phase 3, Phase 2. Its lead program is Imlifidase (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hansa Biopharma AB's next FDA catalyst?→
Hansa Biopharma AB's (HNSA.ST) next tracked catalyst is a Phase 2 expected February 28, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HNSA.ST biotech catalysts?→
Add HNSA.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hansa Biopharma AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.